Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.

Chen J. et al, (2023), Alimentary pharmacology & therapeutics, 57, 1034 - 1035

Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.

Chen J. et al, (2023), Alimentary pharmacology & therapeutics, 57, 1048 - 1049

Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.

Zhao J. et al, (2023), Gut

Defining Interactions Between the Genome, Epigenome, and the Environment in Inflammatory Bowel Disease: Progress and Prospects.

Noble AJ. et al, (2023), Gastroenterology

Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank.

Chen J. et al, (2023), Journal of Crohn's & colitis, 17, 535 - 552

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.

Adams A. et al, (2023), Gut, 72, 433 - 442

Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research

Alexander JL. et al, (2023), Gut

The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.

Sun Y. et al, (2023), Am J Gastroenterol

Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Shubhakar A. et al, (2023), Journal of Crohn's and Colitis

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Louis E. et al, (2023), Lancet Gastroenterol Hepatol

Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.

Chen J. et al, (2023), Alimentary pharmacology & therapeutics

Bi-directional Mendelian randomization analysis provides evidence for the causal involvement of dysregulation of CXCL9, CCL11 and CASP8 in the pathogenesis of ulcerative colitis.

Chen J. et al, (2022), Journal of Crohn's & colitis

Long-term temporal stability of peripheral blood DNA methylation profiles in patients with inflammatory bowel disease.

Joustra V. et al, (2022), Cellular and molecular gastroenterology and hepatology

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.

Selim R. et al, (2022), The lancet. Gastroenterology & hepatology

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Wellens J. et al, (2022), Gut, 71, 1919.2 - 1922

Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.

Kalla R. et al, (2022), Journal of Crohn's & colitis

Systematic Review and Meta-analysis of Peripheral Blood DNA methylation studies in Inflammatory Bowel Disease.

Joustra V. et al, (2022), Journal of Crohn's & colitis

Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Serra EG. et al, (2022), Nature Communications, 13

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis

Hart A. et al, (2022), United European Gastroenterology Journal, 10, 485 - 495

Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn’s disease

Zhang S. et al, (2022), JCI Insight, 7

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?